Cellectar Biosciences, Inc. CLRB
1.25 USD +0.10 (+8.70%)
At closeNov 6, 2026, 4:23 PM EST
1.22 -0.03 -2.40%
After hours · Nov 6, 4:23 PM ET
1.13 Day range 1.28
1.12 52-week range 4.04
- YTD
- -57.63%
- 1 year
- -63.56%
News
benzinga.com Cellectar Biosciences To Present Three Posters For Its Radiopharmaceutical Candidate At American Society Of Hematology Annual Meeting Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of cancer therapies, today announced that three posters…
globenewswire.com Cellectar Biosciences to Present Three Posters Highlighting Durable Clinical Activity of Iopofosine I 131 in Waldenström Macroglobulinemia at the American Society of Hematology Annual Meeting and Exposition Updated CLOVER WaM Phase 2b analyses show durable responses in heavily pretreated patients and suggest greater benefit when used earlier in treatment paradigm Company to present Phase 3…
globenewswire.com Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Tuesday, November 10, 2026 FLORHAM PARK, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for…
benzinga.com Cellectar Biosciences Reports Results From Case Study Highlighting Durable Complete Response In Heavily Pretreated Patient With Diffuse Large B-Cell Lymphoma Treated With Iopofosine I 131 Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential…